Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis

Archives of Dermatology

Volumn 146, Issue 8, 2010, Pages 918-919

  Lillis, Joseph V ^a,b   Guo, Chang Sheng ^d   Lee, Jennifer J ^b   Blauvelt, Andrew ^b,c,d  

^a UCSD MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 23;

CELL COUNT; CELL LABELING; CHRONIC DISEASE; CLINICAL ARTICLE; DERMATITIS; DISEASE ASSOCIATION; DISEASE DURATION; FROZEN SECTION; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; HYPERKERATOTIC HAND DERMATITIS; INCUBATION TIME; INSTITUTIONAL REVIEW; LETTER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; PUNCH BIOPSY; PUSTULOSIS PALMOPLANTARIS; TISSUE SECTION; BIOPSY; FOOT; GENETICS; HAND; METABOLISM; PALMOPLANTAR KERATODERMA; PATHOLOGY; PSORIASIS; UPREGULATION;

BIOPSY; CHRONIC DISEASE; FOOT; HAND; HUMANS; INTERLEUKIN-23; KERATODERMA, PALMOPLANTAR; PSORIASIS; UP-REGULATION;

EID: 77955855307     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.168     Document Type: Letter

References (5)

1. Hersle K, Mobacken H. Hyperkeratotic dermatitis of the palms. Br J Dermatol. 1982;107(2):195-201.
2. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350.
3. Thestrup-Pedersen K, Andersen KE, Menne T, Veien NK. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin: a single-blind placebo controlled study. Acta Derm Venereol. 2001;81 (5):353-355. (Pubitemid 34019180)
4. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, inpatients with psoriasis:76-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 1). Lancet. 2008;371(9625):1665- 1674.
5. Papp KA, Langley RG, Lebwohl M, et al; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675- 1684.